UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (7), p.896-905

2018

Volltextzugriff (PDF)

Systematic review: safety of mesalazine in ulcerative colitis

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (12), p.1597-1609

2018

Volltextzugriff (PDF)

Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease

Alimentary pharmacology & therapeutics, 2016-02, Vol.43 (3), p.317-333

2016

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

Systematic review: fertility in non‐surgically treated inflammatory bowel disease

Alimentary Pharmacology & Therapeutics (Suppl), 2013-10, Vol.38 (8), p.847-853

2013

Volltextzugriff (PDF)

Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitis

Alimentary pharmacology & therapeutics, 2017-06, Vol.45 (12), p.1481-1492

2017

Volltextzugriff (PDF)

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

Gut, 2006-06, Vol.55 (6), p.749-753

2006

Volltextzugriff (PDF)

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

The American journal of gastroenterology, 2015-09, Vol.110 (9), p.1324-1338

2015

Volltextzugriff (PDF)

Factors associated with pregnancy outcome in anti‐TNF treated women with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2014-08, Vol.40 (4), p.363-373

2014

Volltextzugriff (PDF)

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis

Alimentary pharmacology & therapeutics, 2015-04, Vol.41 (8), p.734-746

2015

Volltextzugriff (PDF)

The features of mucosa‐associated microbiota in primary sclerosing cholangitis

Alimentary pharmacology & therapeutics, 2016-04, Vol.43 (7), p.790-801

2016

Volltextzugriff (PDF)

Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future

Alimentary Pharmacology & Therapeutics (Suppl), 2013-05, Vol.37 (9), p.855-866

2013

Volltextzugriff (PDF)

Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience

Alimentary pharmacology & therapeutics, 2011-04, Vol.33 (8), p.857-869

2011

Volltextzugriff (PDF)

Editorial: biologics in inflammatory bowel disease―time for direct comparisons

Alimentary pharmacology & therapeutics, 2017-07, Vol.46 (1), p.68-69

2017

Volltextzugriff (PDF)

Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-09, Vol.34 (5), p.533-543

2011

Volltextzugriff (PDF)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

Alimentary pharmacology & therapeutics, 2013-11, Vol.38 (10), p.1236-1247

2013

Volltextzugriff (PDF)

One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

Alimentary pharmacology & therapeutics, 2013-01, Vol.37 (2), p.204-213

2013

Volltextzugriff (PDF)

The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10‐ to 19‐year‐old age bracket (1988–2007)

Alimentary pharmacology & therapeutics, 2011-05, Vol.33 (10), p.1133-1142

2011

Volltextzugriff (PDF)

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (2), p.219-228

2018

Volltextzugriff (PDF)

Editorial: de novo inflammatory bowel disease following bariatric surgery—potential implications for research and clinical practice. Authors’ reply

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (11), p.1540-1540

2018

Volltextzugriff (PDF)

Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-09, Vol.34 (5), p.497-508

2011

Volltextzugriff (PDF)

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1296-1309

2010

Volltextzugriff (PDF)

Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn's Disease

mBio, 2016-09, Vol.7 (5)

2016

Volltextzugriff (PDF)

Lymphatics, tertiary lymphoid organs and the granulomas of Crohn’s disease: an immunohistochemical study

Alimentary pharmacology & therapeutics, 2011-04, Vol.33 (8), p.930-939

2011

Volltextzugriff (PDF)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.264-275

2017

Volltextzugriff (PDF)

1 – 25 von 963

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(845)
Mit Volltextzugriff
(742)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(445)
Science & Technology
(380)
Life Sciences & Biomedicine
(375)
Gastroenterology & Hepatology
(291)
Male
(280)
Female
(264)
Adult
(259)
Biological And Medical Sciences
(201)
Middle Aged
(191)
Medical Sciences
(189)
Gastroenterology. Liver. Pancreas. Abdomen
(136)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(129)
Other Diseases. Semiology
(125)
Adolescent
(100)
Aged
(91)
Inflammatory Bowel Disease
(91)
Crohn's Disease
(84)
Crohn Disease - Drug Therapy
(62)
Pharmacology & Pharmacy
(59)
Crohn Disease - Genetics
(53)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease

Systematic review: safety of mesalazine in ulcerative colitis

Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Systematic review: fertility in non‐surgically treated inflammatory bowel disease

Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitis

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

Factors associated with pregnancy outcome in anti‐TNF treated women with inflammatory bowel disease

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis

The features of mucosa‐associated microbiota in primary sclerosing cholangitis

Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future

Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience

Editorial: biologics in inflammatory bowel disease―time for direct comparisons

Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10‐ to 19‐year‐old age bracket (1988–2007)

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Editorial: de novo inflammatory bowel disease following bariatric surgery—potential implications for research and clinical practice. Authors’ reply

Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn's Disease

Lymphatics, tertiary lymphoid organs and the granulomas of Crohn’s disease: an immunohistochemical study

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

Suchergebnisse filtern